CV Therapeutics starts Phase II CHF trial

CVTX began a U.S. placebo-controlled Phase II trial of oral ranolazine, a partial fatty acid oxidation (pFOX) inhibitor anti-ischemic agent, in patients with severe congestive heart failure (CHF). The...